Secondary malignant neoplasm of bladder
ICD-10 C79.11 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of bladder.
C79.11 refers to secondary malignant neoplasms of the bladder, indicating that the cancer has metastasized to the bladder from another primary site. This condition is often seen in patients with a history of malignancies such as breast, lung, or prostate cancer. The bladder serves as a site for metastatic disease due to its vascular supply and anatomical proximity to other organs. Patients may present with hematuria, urinary obstruction, or other urinary symptoms. Diagnosis typically involves imaging studies, such as CT scans or MRIs, and cystoscopy with biopsy to confirm the presence of malignant cells. Staging of the disease is crucial, as it influences treatment options and prognosis. The management of secondary malignant neoplasms often focuses on palliative care, especially when the primary tumor is advanced or when the metastatic disease is extensive. Treatment may include chemotherapy, radiation therapy, or supportive care to alleviate symptoms and improve quality of life.
Detailed history of primary malignancy, staging information, and treatment plans.
Patients with known primary cancers presenting with urinary symptoms.
Ensure clear documentation of the metastatic process and treatment intent.
Cystoscopy findings, biopsy results, and imaging studies.
Patients with hematuria and a history of cancer.
Document the extent of bladder involvement and any surgical interventions.
Used for diagnosis and evaluation of bladder lesions.
Cystoscopy findings and any biopsy results.
Urologists must document the extent of the procedure and findings.
Accurate coding of C79.11 is crucial for proper treatment planning, reimbursement, and cancer registry reporting. It ensures that patients receive appropriate care based on their metastatic disease status.
